Annals of Oncology, 0923-7534

Journal

  1. 2019
  2. Levy, S., Aarts, M. J. B., Eskens, F. A., Keymeulen, K., Been, L., Grunhagen, D. J., ... Tesselaar, M. E. T. (2019). Avelumab for advanced Merkel cell carcinoma in the Netherlands: A nationwide survey. Annals of Oncology, 30, 537-538.
  3. Lee, D. H., Kim, D-W., Camidge, D. R., Langer, C. J., Huber, R. M., Tiseo, M., ... Ahn, M-J. (2019). Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial. Annals of Oncology, 30, 634-635.
  4. Creutzberg, C. L., Leon-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., ... Bosse, T. (2019). Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. Annals of Oncology, 30, 899-900.
  5. Dieras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J-P., ... Arun, B. K. (2019). Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Annals of Oncology, 30, 857-858.
  6. Burgers, S. A., de Gooijer, C., Cornelissen, R., Aerts, J. G., Biesma, B., Heemst, R. V., ... Stigt, J. (2019). Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). Annals of Oncology, 30.
  7. Groenland, S. L., Van Eerden, R. A. G., Koolen, S. L., Moes, D. J. A. R., Desar, I. M. E., Touw, D. J., ... Steeghs, N. (2019). Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study. Annals of Oncology, 30.
  8. Lindsay, C. R., Blackhall, F. H., Carmel, A., Gazzaniga, P., Groen, H. J. M., Krebs, M. G., ... Michiels, S. (2019). EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. Annals of Oncology, 30 (Suppl 2), ii7. https://doi.org/10.1093/annonc/mdz073
  9. 2018
  10. van Zeijl, M. C. T., Wouters, M. W. J. M., van den Eertwegh, A. J., Aarts, M. J., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., ... Haanen, J. B. A. G. (2018). Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population. Annals of Oncology, 29(Suppl.8), viii455. [1276P]. https://doi.org/10.1093/annonc/mdy289.032
  11. van Veggel, B., van der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., ... De Langen, J. (2018). Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer. Annals of Oncology, 29(Suppl.8), viii524-viii525. https://doi.org/10.1093/annonc/mdy292.072
  12. ESMO Guidelines Committee and EURACAN, Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., ... Van der Graaf, W. (2018). Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29(Suppl.4), 51-67. https://doi.org/10.1093/annonc/mdy096
  13. Oosting, S., Desideri, I., Staelens, D., Caballero, C., Tribius, S., Simon, C., ... Luciani, A. (2018). Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results from an EORTC led survey. Annals of Oncology, 29(Suppl_8), 393-393.
  14. Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., ... Horwich, A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology, 29(8), 1658-1686. https://doi.org/10.1093/annonc/mdy217
  15. Wang, H., Agulnik, J., Kasymjanova, G., Wang, A., Jiménez, P., Cohen, V., ... Spatz, A. (2018). Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Annals of Oncology, 29(6), 1417-1422. https://doi.org/10.1093/annonc/mdy126
  16. Cardoso, F., Bartlett, J. M. S., Slaets, L., van Deurzen, C. H. M., van Leeuwen-Stok, E., Porter, P., ... Giordano, S. H. (2018). Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals of Oncology, 29(2), 405-417. https://doi.org/10.1093/annonc/mdx651
  17. 2017
  18. van der Velden, D. L., van Herpen, C. M. L., van Laarhoven, H. W. M., Smit, E. F., Groen, H. J. M., Willems, S. M., ... Voest, E. E. (2017). Molecular Tumor Boards: Current practice and future needs. Annals of Oncology, 28(12), 3070-3075. https://doi.org/10.1093/annonc/mdx528
  19. Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J. -Y., ... de Vries, E. G. E. (2017). ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology, 28(10), 2340-2366. https://doi.org/10.1093/annonc/mdx310
  20. Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., ... Gotlib, J. (2017). Midostaurin: A magic bullet that blocks mast cell expansion and activation. Annals of Oncology, 28(10), 2367-2376. https://doi.org/10.1093/annonc/mdx290
Previous 1 2 3 4 Next

ID: 13479495